Actively Recruiting
Phase II Study of Carbon Ion Radiotherapy for Frail Adults With Non-Metastatic Pancreatic Cancer Not Suitable for Surgery or Chemotherapy
Led by Yonsei University · Updated on 2025-12-02
33
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of carbon ion radiotherapy in frail patients diagnosed with non-metastatic pancreatic cancer who cannot undergo surgery or systemic chemotherapy. Frailty is defined by a Clinical Frailty Scale score of 4 or higher or by significant medical conditions that limit aggressive treatments. This phase II study aims to assess the treatments impact on overall survival, progression-free survival, tumor control, side effects, and quality of life. Participants will receive carbon ion radiotherapy delivered through one of two schedules either 55.2 Gy over 12 fractions in 3 weeks or 40-48 Gy over 4 fractions in 1 week. Treatment planning uses advanced imaging techniques including 4D-CT to target the tumor and high-risk areas while protecting nearby organs such as the stomach, liver, and kidneys. Treatments are given daily or on alternate days depending on the chosen regimen, with weekly evaluations to adjust plans if needed. During the study, participants will undergo baseline imaging, laboratory tests, frailty assessments, and quality-of-life questionnaires. Follow-up visits occur 1 to 3 months after treatment and then every 3 to 6 months for up to 2 years, including imaging, toxicity monitoring, tumor marker checks, and repeated quality-of-life surveys. The main measure is overall survival over two years, with secondary outcomes including tumor control, treatment side effects, and quality of life changes.
CONDITIONS
Brief Title
Carbon Ion Radiotherapy in Frail Patients With Pancreatic Cancer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here